dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorMcMaster University, McMaster Institute of Urology
dc.contributorPediatric Pulmonology, PGIMER
dc.date.accessioned2018-12-11T17:25:43Z
dc.date.available2018-12-11T17:25:43Z
dc.date.created2018-12-11T17:25:43Z
dc.date.issued2015-01-01
dc.identifierClinics, v. 70, n. 9, p. 618-622, 2015.
dc.identifier1807-5932
dc.identifierhttp://hdl.handle.net/11449/177491
dc.identifier10.6061/clinics/2015(09)04
dc.identifierS1807-59322015000900618
dc.identifier2-s2.0-84941619611
dc.identifierS1807-59322015000900618.pdf
dc.identifier7199562550978496
dc.identifier8745358989680600
dc.identifier9465938306255342
dc.identifier260120486355934
dc.identifier0000-0002-2323-9159
dc.identifier0000-0002-4081-803X
dc.identifier0000-0002-6977-4165
dc.identifier0000-0002-9362-1505
dc.description.abstractOBJECTIVE: We refer to the effectiveness (known as pragmatic or real world) and efficacy (known as explanatory or desired or ideal world) of interventions. However, these terms seem to be randomly chosen by investigators who design clinical trials and do not always reflect the true purpose of the study. A pragmaticexplanatory continuum indicator summary tool was thus developed with the aim of identifying the characteristics of clinical trials that distinguish between effectiveness and efficacy issues. We verified whether clinical trials used the criteria proposed by the indicator summary tool, and we categorized these clinical trials according to a new classification. METHOD: A systematic survey of randomized clinical trials was performed. We added a score ranging from 0 (more efficacious) to 10 (more effective) to each domain of the indicator summary tool and proposed the following classifications: high efficacy (<25), moderate efficacy (25-50), moderate effectiveness (51-75), and high effectiveness (<75). RESULTS: A total of 844 randomized trials were analyzed. No analyzed trials used the criteria proposed by the indicator summary tool. Approximately 44% of the trials were classified as having moderate effectiveness, and 43.82% were classified as having moderate efficacy. CONCLUSIONS: Most clinical trials used the term “efficacy” to illustrate the application of results in clinical practice, but the majority of those were classified as having moderate effectiveness according to our proposed score. The classification based on the 0-100 score is still highly subjective and can be easily misunderstood in all domains based on each investigator’s own experiences and knowledge.
dc.languageeng
dc.relationClinics
dc.relation0,536
dc.rightsAcesso aberto
dc.sourceScopus
dc.subjectClinical medicine
dc.subjectClinical trials
dc.subjectEffectiveness
dc.subjectEfficacy
dc.subjectEvidence-based medicine
dc.subjectResearch
dc.titleDifferences between the real and the desired worlds in the results of clinical trials
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución